#Paris #France #gene therapy #Eligo Bioscience #immuno-dermatology

Eligo Bioscience Secures Major Funding for Genetic Breakthrough

Eligo Bioscience, a frontrunner in the innovation of genetic medicines, has recently announced a significant achievement by securing a grant of $5 million from the French government. This funding is part of an initiative called "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under the France 2030 strategy, facilitated by Bpifrance.

The purpose of this substantial financial support is to expedite the scaling and advancement of Eligo’s proprietary topical gene delivery platform. This platform is uniquely designed to leverage skin-resident bacteria for the local production of therapeutic biologics, a method that aims to transform immuno-dermatological treatments.

With recent key milestones adding to its momentum, including the publication of its microbiome base-editing platform in the prestigious journal Nature, Eligo has strengthened its patent portfolio significantly. The company has secured foundational patents that cover in situ editing of the skin microbiome, culminating in a successful $35 million Series B funding round. These achievements position Eligo with important capabilities to enhance its clinical pipeline rapidly.

Accelerating Towards Clinical Trials

The company has ambitious plans as it aims to build on its first-generation CRISPR-based topical therapy that targets moderate to severe acne vulgaris. The recent funding will allow Eligo to optimize and scale its bioproduction process for this innovative gene delivery vector, setting the stage for advanced clinical trials. In this significant endeavor, Eligo is collaborating with Biose Industries, a recognized Contract Development and Manufacturing Organization (CDMO) specializing in microbial fermentation. Biose brings in extensive expertise in good manufacturing practices (GMP) essential for fast-tracking the clinical validation of Eligo’s breakthroughs.

Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience, expressed optimism stating, "This funding empowers us to establish a robust bioproduction process for our pioneering topical microbiome-targeting gene-editing therapies. It lays the groundwork for expanding into a wide range of immuno-dermatological indications." His statement emphasizes the company's commitment to delivering transformative therapeutic solutions to meet critical medical needs faced by patients worldwide.

Exploring New Therapeutic Avenues

Eligo's innovative approach revolves around understanding the pivotal role the skin microbiome plays in regulating immune responses. The specific targeting of commensal bacteria found within hair follicles allows the company to employ these microorganisms as localized bioreactors. This unique in-situ delivery methodology enables the precise expression of high-potency biologics directly at sites where immune dysregulation occurs.

The grant funding will fuel the exploration of various therapeutic payloads and will contribute to the creation of a diversified immuno-dermatology pipeline. This pipeline focuses on addressing chronic inflammatory and immune-mediated skin diseases that remain with significant unmet clinical needs.

For more information about Eligo Bioscience, and their exciting journey towards innovative medical solutions, you can visit their website and learn more about the France 2030 initiative as well as details from Bpifrance.

Eligo Bioscience continues to demonstrate its commitment to revolutionizing gene therapy, potentially reshaping treatment paradigms for dermatological conditions worldwide.